Markets:

Overview

News

Currencies

International

Treasuries

Roche Holding Div RTS (OP:RHHVF)

464.40 +5.89 (+1.28%)

Streaming Delayed Price Updated: 3:24 PM EDT, Aug 21, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Roche Holding Div RTS

< Previous 1 2 3 4 5 6 7 Next >

Exelixis Will Not Pursue Untreated Liver Cancer Indication For Cabometyx Combo Therapy ↗

March 15, 2022

Exelixis Inc (NASDAQ: EXEL) announced results from the final analysis of the second primary endpoint of overall survival (OS) from the phase 3 COSMIC-312 trial of Cabometyx (cabozantinib) plus...

Via Benzinga

Sanofi-Regeneron's Dupixent Falls Short In Chronic Spontaneous Urticaria Trial ↗

February 18, 2022

Sanofi SA (NASDAQ: SNY) and Regeneron Pharmaceuticals Inc (NASDAQ: REGN) have reported disappointing results from the Phase 3 trial of Dupixent (dupilumab...

Via Benzinga

Roche Expects Slower FY22 Sales Growth On Lower Demand For COVID-19 Tests ↗

February 03, 2022

Roche Holdings AG's (OTC: RHHBY) FY21 sales increased 8% Y/Y (9% on a constant currency basis) to CH

Via Benzinga

Novartis Expects FY22 Sales, Profit Growth; Sandoz Review Continues ↗

February 02, 2022

Novartis AG (NYSE: NVS) reported a Q4 net income of $16.31 billion, up from $2.1 billion the previous year,

Via Benzinga

Biogen Exercises Option To Participate Developing Genentech's Bispecific Antibody, Mosunetuzumab ↗

February 01, 2022

Biogen Inc (NASDAQ: BIIB) has

Via Benzinga

FDA Approves First Injectable Eye Medicine For Vision Loss Disorder - Genentech's Vabysmo ↗

January 31, 2022

The FDA has approved Genentech's, a unit of

Via Benzinga

Genentech's Evrysdi Application Under FDA Priority Review For Use In Babies Below 2 Months ↗

January 25, 2022

The FDA has granted priority review for Genentech's, a unit of Roche Holdings AG (OTC: RHHBY) supplemental marketing application for Evrysdi (...

Via Benzinga

CMS Proposes Coverage Of Biogen's Alzheimer's Drug, With Conditions Apply ↗

January 12, 2022

The Centers for Medicare & Medicaid Services (CMS) released a proposed national coverage determination for Medicare to cover drugs that target amyloid for mild...

Via Benzinga

Lineage, Genentech Ink Cell Therapy Licensing Pact For Ocular Diseases ↗

December 20, 2021

Lineage Cell Therapeutics Inc (NYSE: LCTX) has entered into an exclusive worldwide collaboration and license agreement with Roche Holdings AG's (OTC: RHHBY)...

Via Benzinga

Novartis Launches New Share Buyback Program Of Up To $15B ↗

December 16, 2021

Novartis AG (NYSE: NVS) is launching a new share buyback worth up to $15 billion to be executed by the end of 2023, adding it was confident in its top-line growth...

Via Benzinga

After Roche Walks Away, Atea Puts Break On Late-Stage COVID-19 Oral Antiviral Trial ↗

December 15, 2021

Atea Pharmaceuticals Inc (NASDAQ: AVIR) said it would close the global Phase 3 MORNINGSKY trial. The decision comes after considering the changing COVID-19 landscape...

Via Benzinga

Roche's Polivy Combo Boosts Survival In Early-Stage Lymphoma Patients ↗

December 14, 2021

Roche Holdings AG (OTC: RHHBY) announced results from the Phase 3 POLARIX study of Polivy (polatuzumab vedotin) with MabThera/Rituxan (rituximab) and the chemotherapy regimen...

Via Benzinga

Roche Uncorks Favorable Responses From Mosunetuzumab In Follicular Lymphoma Settings ↗

December 13, 2021

Roche Holdings AG's (OTC: RHHBY) mosunetuzumab, a bispecific targeting the CD20 protein on the surface of tumors and the CD3 protein on T cells, posted a 60%...

Via Benzinga

Infinity Pharma Shares Updated Eganelisib Combo Therapy In Breast Cancer Trial ↗

December 10, 2021

Infinity Pharmaceuticals Inc (NASDAQ: INFI) presented updated data from the ongoing MARIO-3 study during the 2021 San Antonio Breast Cancer Symposium (SABCS)....

Via Benzinga

Roche Posts Encouraging Follow-up Data From Tiragolumab/Tecentriq Trial In Lung Cancer ↗

December 10, 2021

Roche Holdings AG (OTC: RHHBY) reported follow-up efficacy, safety, and patient-reported outcomes data from the Phase 2 CITYSCAPE trial of tiragolumab plus...

Via Benzinga

Europe Approves Roche's Tocilizumab For Patients With Severe COVID-19 ↗

December 07, 2021

The European Commission has extended the marketing authorization for Roche Holdings AG's (OTC: RHHBY) Actemra/RoActemra (Tocilizumab) to treat patients with severe...

Via Benzinga

Immunocore' ImmTAC Candidate Shows Early Response In Ovarian And Head & Neck Cancer Patients ↗

December 06, 2021

Immunocore Holdings Plc (NASDAQ: IMCR) announced the initial Phase 1 data of IMC-C103C, a bispecific T cell engager targeting MAGE-A4, in selected advanced solid...

Via Benzinga

Biden's New COVID-19 Plan Includes Reimbursement For Over The Counter, At-Home COVID Tests ↗

December 03, 2021

President Biden announced that private health insurance plans would soon reimburse people who buy over-the-counter (OTC), at-home rapid tests for COVID-19. What Happened...

Via Benzinga

Gene Therapy-Focused Dyno Therapeutics Adds Astellas To List Partner List With $1.6B Pact ↗

December 02, 2021

Gene therapy startup Dyno Therapeutics Inc has partnered with pharmaceutical giants such as Novartis AG (NYSE: NVS) and Roche Holdings AG (OTC: RHHBY...

Via Benzinga

Roche's Gavreto Conditionally Approved In Europe For RET Fusion-Positive Lung Cancer ↗

November 19, 2021

The European Commission (EC) has granted conditional marketing authorization to Roche Holdings AG's (OTC: RHHBY) Gavreto (pralsetinib) for treating adults...

Via Benzinga

Novartis Has $21B From Roche Stake Sale - Which Company Is On Its M&A Radar? ↗

November 18, 2021

Novartis AG (NYSE: NVS) is getting a massive influx of cash from selling its 20-year stake in Roche Holdings AG (OTC: RHHBY), triggering speculation...

Via Benzinga

Spark Therapeutics' Hemophilia Gene Therapy Shows Reduction In Bleeding Episodes ↗

November 18, 2021

Spark Therapeutics, a unit of Roche Holdings AG (OTC: RHHBY), has announced data from its Phase 1/2 trial of SPK-8011 in hemophilia A. At a median efficacy follow-up of 33.4...

Via Benzinga

Atea Shares Plunge As Roche Culls Partnership To Develop COVID-19 Pill ↗

November 17, 2021

Roche Holdings AG (OTC: RHHBY) has ended a partnership with Atea Pharmaceuticals Inc (NASDAQ: AVIR) to jointly develop a COVID-19 antiviral pill, a month...

Via Benzinga

Europe Approves Regeneron - Roche's COVID-19 Antibody Cocktail ↗

November 12, 2021

The European Commission (EC) has approved Regeneron Pharmaceuticals Inc's (NASDAQ: REGN) COVID-19 antibody cocktail, known as REGEN-COV in the U.S. and...

Via Benzinga

EU Regulator Backs Regeneron-Roche's COVID-19 Drug ↗

November 11, 2021

The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Regeneron Pharmaceuticals Inc...

Via Benzinga

Hit By Slow Rollout, Biogen's Aduhelm Could Soon Find Itself In Price Competition: Reuters ↗

November 10, 2021

With already a snail-paced rollout of Biogen Inc's (NASDAQ: BIIB) controversial Alzheimer's treatment Aduhelm, the Company could soon face price competition....

Via Benzinga

ALX Oncology Falls After Updated Data For Solid Tumors Candidate ↗

November 09, 2021

ALX Oncology Holdings Inc (NASDAQ: ALXO) released additional data from a phase 1b trial of evorpacept in solid tumor malignancies. One cohort included gastric/...

Via Benzinga

Regeneron-Roche's COVID-19 Treatment Shows Long Term Benefit After Single Dose ↗

November 08, 2021

Regeneron Pharmaceuticals Inc (NASDAQ: REGN) has announced additional results from a Phase 3 trial, which assessed a single dose of REGEN-COV (1,200 mg...

Via Benzinga

Novartis To Offload Its Stake Back To Roche For $20.7B ↗

November 04, 2021

Novartis AG (NYSE: NVS), a shareholder in Roche Holdings AG (OTC: RHHBY) for more than 20 years, would sell its entire stake, which is nearly one-third voting...

Via Benzinga

Galecto To Test GB1211 Combined with Roche's Tecentriq In First Line Lung Cancer Setting ↗

November 02, 2021

Galecto Inc (NASDAQ: GLTO) has entered into a clinical trial supply agreement with Roche Holdings AG (OTC: RHHBY) to explore the combination of GB1211 in...

Via Benzinga

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Roche Holding Div RTS (OP:RHHVF)

All News about Roche Holding Div RTS

Starting at /week.